SURTAVI – Medtronic CoreValve. Intermediate risk patients are randomized to surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR).
Liberty 360 – multi center clinical study to evaluate long term and acute clinical and economic outcomes of endovascular device intervention in patients with peripheral vascular disease (PAD).
Pegasus – TIMI 54: A randomized, double-blind, multinational trial to assess the prevention of thrombotic events with ticagrelor compared to placebo on a background of aspirin therapy in patients with a history of myocardial infarction.
CoreValve – Continued Access Trial (CAS) This trial evaluates the safety and efficacy of the Medtronic CoreValve System in the treatment of symptomatic severe aortic stenosis in patients requiring aortic valve replacement, with predicted operative mortality or serious, irreversible morbidity risk of >15% and <50% at 30 days.
CoreValve – Expanded Use Trial – This trial evaluates the safety and efficacy of the Medtronic CoreValve system in patients with significant co-morbities in whom the risk of surgical aortic valve replacement has a predicted operative mortality or serious irreversible morbidity risk of >50% at 30 days.
DANCE – Delivery of Dexamethasone to the adventitia to enhance the clinical efficacy after femoro-popliteal revascularization. This study will asess the effects of Dexamethasone delivered directly into the adventitia using the BullFrog Infusion Catheter in patients who undergo revascularization of a stenosis in the lower extremity.
COAPT: Clinical Outcomes Assessment of the MitraClip Percutaneous Therapy for extremely high surgical risk patients. This trial evaluates the safety and effectiveness of the MitraClip System for the treatment of moderate to severe or severe functional mitral regurgitation (FMR) in symptomatic heart failure patients.
TIMI 60: LATITUDE: This study compares the effects of Losmapimod twice daily versus placebo for 12 weeks when added to standard of care in patients with myocardial infarction.